Literature DB >> 33469076

Blood-based protein profiling identifies serum protein c-KIT as a novel biomarker for hypertrophic cardiomyopathy.

Kristina Sonnenschein1,2, Jan Fiedler1, David de Gonzalo-Calvo1,3,4, Ke Xiao1, Angelika Pfanne1, Annette Just1, Carolin Zwadlo2, Samira Soltani2, Udo Bavendiek2, Theresia Kraft5, Cristobal Dos Remedios6, Serghei Cebotari7, Johann Bauersachs2,8, Thomas Thum9,10,11.   

Abstract

Hypertrophic cardiomyopathy (HCM) is one of the most common hereditary heart diseases and can be classified into an obstructive (HOCM) and non-obstructive (HNCM) form. Major characteristics for HCM are the hypertrophy of cardiomyocytes and development of cardiac fibrosis. Patients with HCM have a higher risk for sudden cardiac death compared to a healthy population. In the present study, we investigated the abundancy of selected proteins as potential biomarkers in patients with HCM. We included 60 patients with HCM and 28 healthy controls and quantitatively measured the rate of a set of 92 proteins already known to be associated with cardiometabolic processes via protein screening using the proximity extension assay technology in a subgroup of these patients (20 HCM and 10 healthy controls). After validation of four hits in the whole cohort of patients consisting of 88 individuals (60 HCM patients, 28 healthy controls) we found only one candidate, c-KIT, which was regulated significantly different between HCM patients and healthy controls and thus was chosen for further analyses. c-KIT is a tyrosine-protein kinase acting as receptor for the stem cell factor and activating several pathways essential for cell proliferation and survival, hematopoiesis, gametogenesis and melanogenesis. Serum protein levels of c-KIT were significantly lower in patients with HCM than in healthy controls, even after adjusting for confounding factors age and sex. In addition, c-KIT levels in human cardiac tissue of patients with HOCM were significant higher compared to controls indicating high levels of c-KIT in fibrotic myocardium. Furthermore, c-KIT concentration in serum significantly correlated with left ventricular end-diastolic diameter in HOCM, but not HCM patients. The present data suggest c-KIT as a novel biomarker differentiating between patients with HCM and healthy population and might provide further functional insights into fibrosis-related processes of HOCM.

Entities:  

Year:  2021        PMID: 33469076      PMCID: PMC7815737          DOI: 10.1038/s41598-020-80868-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  41 in total

1.  Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate.

Authors:  Chao-Hung Wang; Nicole Anderson; Shu-Hong Li; Paul E Szmitko; Wen-Jing Cherng; Paul W M Fedak; Shafie Fazel; Ren-Ke Li; Terrence M Yau; Richard D Weisel; William L Stanford; Subodh Verma
Journal:  Circ Res       Date:  2006-08-24       Impact factor: 17.367

2.  Nerve growth factor promotes cardiac repair following myocardial infarction.

Authors:  Marco Meloni; Andrea Caporali; Gallia Graiani; Costanza Lagrasta; Rajesh Katare; Sophie Van Linthout; Frank Spillmann; Ilaria Campesi; Paolo Madeddu; Federico Quaini; Costanza Emanueli
Journal:  Circ Res       Date:  2010-04-01       Impact factor: 17.367

3.  Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

Authors:  Jun Guo; Lu Si; Yan Kong; Keith T Flaherty; Xiaowei Xu; Yanyan Zhu; Christopher L Corless; Li Li; Haifu Li; Xinan Sheng; Chuanliang Cui; Zhihong Chi; Siming Li; Mei Han; Lili Mao; Xuede Lin; Nan Du; Xiaoshi Zhang; Junling Li; Baocheng Wang; Shukui Qin
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544

4.  Essential role of stem cell factor-c-Kit signalling pathway in bleomycin-induced pulmonary fibrosis.

Authors:  Lin Ding; Vladilsav Dolgachev; Zhuang Wu; Tianju Liu; Taku Nakashima; Zhe Wu; Matthew Ullenbruch; Nicholas W Lukacs; Zidi Chen; Sem H Phan
Journal:  J Pathol       Date:  2013-04-03       Impact factor: 7.996

5.  Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.

Authors:  Samuel E Deprimo; Xin Huang; Martin E Blackstein; Christopher R Garrett; Charles S Harmon; Patrick Schöffski; Manisha H Shah; Jaap Verweij; Charles M Baum; George D Demetri
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 12.531

6.  Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Caroline J Coats; Wendy E Heywood; Alex Virasami; Nadia Ashrafi; Petros Syrris; Cris Dos Remedios; Thomas A Treibel; James C Moon; Luis R Lopes; Christopher G A McGregor; Michael Ashworth; Neil J Sebire; William J McKenna; Kevin Mills; Perry M Elliott
Journal:  Circ Genom Precis Med       Date:  2018-12

7.  Therapeutic modulation of RNA-binding protein Rbm38 facilitates re-endothelialization after arterial injury.

Authors:  Kristina Sonnenschein; Jan Fiedler; Angelika Pfanne; Annette Just; Saskia Mitzka; Robert Geffers; Andreas Pich; Johann Bauersachs; Thomas Thum
Journal:  Cardiovasc Res       Date:  2019-10-01       Impact factor: 10.787

8.  Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.

Authors:  Christopher N Toepfer; Amanda C Garfinkel; Gabriela Venturini; Hiroko Wakimoto; Giuliana Repetti; Lorenzo Alamo; Arun Sharma; Radhika Agarwal; Jourdan F Ewoldt; Paige Cloonan; Justin Letendre; Mingyue Lun; Iacopo Olivotto; Steve Colan; Euan Ashley; Daniel Jacoby; Michelle Michels; Charles S Redwood; Hugh C Watkins; Sharlene M Day; James F Staples; Raúl Padrón; Anant Chopra; Carolyn Y Ho; Christopher S Chen; Alexandre C Pereira; Jonathan G Seidman; Christine E Seidman
Journal:  Circulation       Date:  2020-01-27       Impact factor: 29.690

9.  Long Noncoding RNA-Enriched Vesicles Secreted by Hypoxic Cardiomyocytes Drive Cardiac Fibrosis.

Authors:  Franziska Kenneweg; Claudia Bang; Ke Xiao; Chantal M Boulanger; Xavier Loyer; Stephane Mazlan; Blanche Schroen; Steffie Hermans-Beijnsberger; Ariana Foinquinos; Marc N Hirt; Thomas Eschenhagen; Sandra Funcke; Stevan Stojanovic; Celina Genschel; Katharina Schimmel; Annette Just; Angelika Pfanne; Kristian Scherf; Susann Dehmel; Stella M Raemon-Buettner; Jan Fiedler; Thomas Thum
Journal:  Mol Ther Nucleic Acids       Date:  2019-09-13       Impact factor: 8.886

10.  MicroRNA-221 is a potential biomarker of myocardial hypertrophy and fibrosis in hypertrophic obstructive cardiomyopathy.

Authors:  Derong Huang; Zhongxiu Chen; Jie Wang; Yucheng Chen; Daxing Liu; Ke Lin
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

View more
  3 in total

1.  Comprehensive Proteomics Profiling Identifies Patients With Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging in the Hypertrophic Cardiomyopathy Population.

Authors:  Bradley S Lander; Yanling Zhao; Kohei Hasegawa; Mathew S Maurer; Albree Tower-Rader; Michael A Fifer; Muredach P Reilly; Yuichi J Shimada
Journal:  Front Cardiovasc Med       Date:  2022-06-17

2.  Dihydromyricetin ameliorates osteogenic differentiation of human aortic valve interstitial cells by targeting c-KIT/interleukin-6 signaling pathway.

Authors:  Shaoshao Zhang; Leilei Fan; Yongjun Wang; Jianjun Xu; Qiang Shen; Jianhua Xie; Zhipeng Zeng; Tingwen Zhou
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988

Review 3.  Mass-Spectrometry-Based Functional Proteomic and Phosphoproteomic Technologies and Their Application for Analyzing Ex Vivo and In Vitro Models of Hypertrophic Cardiomyopathy.

Authors:  Jarrod Moore; Andrew Emili
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.